Michael Burkes Brophy Sells 1,866 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $93.97, for a total value of $175,348.02. Following the transaction, the chief financial officer now directly owns 67,542 shares in the company, valued at approximately $6,346,921.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $93.14, for a total transaction of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The stock was sold at an average price of $89.55, for a total transaction of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The shares were sold at an average price of $91.38, for a total transaction of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.

Natera Trading Up 3.5 %

NASDAQ NTRA opened at $96.98 on Monday. The firm has a market cap of $11.71 billion, a PE ratio of -25.59 and a beta of 1.38. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The company has a 50 day moving average price of $90.56 and a 200 day moving average price of $69.67.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. As a group, sell-side analysts forecast that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NTRA. Norges Bank purchased a new stake in shares of Natera during the fourth quarter worth about $83,970,000. American Century Companies Inc. grew its position in Natera by 115.7% during the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock worth $73,203,000 after purchasing an additional 887,409 shares during the last quarter. Invesco Ltd. increased its stake in Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock valued at $111,930,000 after purchasing an additional 865,404 shares in the last quarter. Perceptive Advisors LLC raised its holdings in shares of Natera by 289.7% in the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after buying an additional 632,047 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after buying an additional 588,147 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NTRA shares. Canaccord Genuity Group upped their price target on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Craig Hallum started coverage on Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target for the company. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a report on Friday, April 5th. Raymond James downgraded Natera from a “strong-buy” rating to an “outperform” rating and increased their price target for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group increased their target price on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.